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January 19, 2010:255–69s Appropriate Use Criteria
or Cardiac Radionuclide
maging in Asymptomatic
iabetic Patients Evidence Based?
e write in reference to the recent article in the Journal, the 2009
ppropriate Use Criteria for Cardiac Radionuclide Imaging
RNI), which was published by the American College of Cardi-
logy and endorsed by many other professional societies (1). This
ocument was anticipated to impact physician decision making,
est performance, and reimbursement policy.
We find the use of RNI for asymptomatic patients with diabetes
ellitus (patients 40 years old) and other coronary risk equiva-
ents that were considered appropriate in that document without
ufficient evidence. Diabetic patients have a high incidence of
oronary artery disease (CAD); therefore, an intensive primary and
econdary prevention is recommended by various professional
ocieties. But the strategy of routine RNI for all asymptomatic
atients cannot be considered appropriate. The DIAD (Detection
f Ischemia in Asymptomatic Diabetics) study was a prospective
andomized trial evaluating outcomes after screening for asymp-
omatic CAD in type 2 diabetic patients (2). Although the study
as underpowered to detect the pre-specified difference, due to a
ow rate of cardiac events, it ruled out any major benefit of routine
creening. Even moderate or large defects had a positive predictive
alue of just 12% for cardiac events. Also, there was no apparent
ifference in the use of interventions for risk modifications between
he 2 groups based upon results of screening. The recent BARI 2D
Bypass Angioplasty Revascularization Investigation in Type 2
iabetes) trial, which randomly assigned patients with type 2
iabetes and stable CAD to immediate revascularization with
ntensive medical therapy versus only intensive medical therapy,
ailed to show to any difference in mortality or major cardiovascular
vents (3). The COURAGE (Clinical Outcomes Utilizing Revas-
ularization and Aggressive Drug Evaluation) trial also showed
hat percutaneous intervention with optimal medical therapy was
o better than optimal medical therapy alone for patients with
table CAD in general and for a subgroup of patients with diabetes
pecifically (4).
Thus, so far, revascularization has not proven beneficial for
atients with asymptomatic or stable patients with CAD in terms
f mortality and major cardiac events. A possible benefit of relief
rom angina does not hold true for subjects who are asymptomatic
t baseline. In all of these trials, large proportions of patients in
oth groups received aggressive evidence-based interventions for
ardiovascular risk reduction as recommended by various profes-
ional societies, and that could explain the low event rates. So, if an
ggressive risk reduction strategy for asymptomatic high-risk
atients can lead to a substantial decrease in cardiac events without
ny additional benefit from revascularization, the role of additional
ardiac RNI is unclear. Routine RNI can be of use, if we can
dentify a subgroup of asymptomatic patients with additional risk
actors who can benefit from revascularization or screening. The
merican Diabetic Association acknowledges the dearth of evi-
ence in support of screening asymptomatic diabetic patients for
AD, and deemed it controversial (5). oThe Centers for Disease Control estimates that about 33.9% of
he U.S. population older than 40 years of age have diabetes (6). As
er the appropriate use criteria, these patients would represent a
igh-risk group for whom cardiac RNI would be considered
ppropriate. In most places, a cardiac RNI would cost about U.S.
700 to $1,400. That would put enormous pressure on health care
esources without any clear benefit.
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eply
e greatly appreciate the comments of Dr. Sethi and colleagues
egarding the use of radionuclide imaging (RNI) in an asymptom-
tic but high-risk patient, such as one with diabetes mellitus, which
onstitutes one of the indications noted in the recently published RNI
ppropriate use criteria (AUC) (1). Their letter correctly describes the
ow event rate noted in the DIAD (Detection of Ischemia in
symptomatic Diabetics) study (2). Furthermore, information from
he BARI-2D (Bypass Angioplasty Revascularization Investigation in
ype 2 Diabetes) study (3), as well as that from the COURAGE
Clinical Outcomes Utilizing Revascularization and Aggressive Drug
valuation) study (4), fails to support the benefit of revascularization,
t least with regard to major cardiovascular events. At the present
ime, diabetic patients are still considered by clinical practice guide-
ines to be a high-risk/coronary artery disease-equivalent cohort,
lthough that may change in the future. However, neither the
ARI-2D study nor the DIAD study data were available at the time
f the rating for the radionuclide AUC. Additionally, both of these
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January 19, 2010:255–69rials had a highly selected population of diabetic patients, which may
ot be representative of the risk for cardiovascular events in the
eneral diabetic population.
Perhaps more importantly, the method for development of
UC is rigorous and does not permit alteration of the final scores
nd classification by the technical (rating) panel. Additionally, the
UC do not state that testing “must” be performed, only that it is
easonable given the clinical scenario and the available medical
nowledge/experience. AUC are therefore not equivalent to a
lass I clinical practice guideline.
Although the COURAGE nuclear substudy was underpowered
o detect differences in treatment approaches, those subjects who
xperienced a reduction of ischemia on single-positron emission
omputed tomography myocardial perfusion imaging had a supe-
ior outcome, although this difference was lost when further risk
djusted. Therefore, we agree with the opinion of Dr. Sethi and
olleagues that “routine RNI can be of use, if we can identify a
ubgroup of asymptomatic patients . . . who can benefit from
evascularization.” This thereby allows the indication to be con-
idered “appropriate” or reasonable in the parlance of AUC.
We agree that, in light of the newer trials, it may not be
ccurate to place patients with only the risk factor of diabetes
nto the high-risk category. However, based on available infor-
ation, we believe that the rating by the technical panel was
easonable. We await additional information on the best way for
isk assessment of patients and will certainly consider revising
he AUC as new evidence becomes available. Thank you for
our thoughtful comments.
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ata Prior to Food and Drug
dminstration Approval
e read with great interest the recent paper by Hsich and Piña (1)
hat examined the many aspects in which we lack data for heart
ailure in women. We wholeheartedly agree that heart failure trials
ust include more women and must provide more sex-specific
ata, and we further believe that there must be evidence of net
enefit in women before Food and Drug Administration approval
or devices to be implanted in critically ill patients.
For example, the authors mention that the recent approval of the
horatec HeartMate II (Thoratec Corporation, Pleasanton, Califor-
ia) will allow more implantation of ventricular assist devices in
omen and will provide prospective data through the Interagency
egistry for Mechanically Assisted Circulation registry. However, the
evice was approved based on data from only 44 women, who
onstituted 23% of the overall study population. The Food and Drug
dministration’s Summary of Safety and Effectiveness Data for this
evice noted that the small number of women “makes it difficult to
raw any conclusions regarding differences in safety profile of the
evice between men and women” (2). Even so, it is worrisome that
omen had an increased rate of some important adverse events,
ncluding a 3-fold higher incidence of stroke (18% vs. 6% in men) and
rends toward a higher incidence of bleeding and infection events.
hese risks may be worthwhile if the device had proven benefit, but
t is concerning that the device’s success rate did not meet the
re-specified end point for success (2).
Therefore, we agree with the authors that a post-approval
egistry to collect data on outcomes in women for this device will
rovide needed information. However, requiring evidence of
enefit in women before Food and Drug Administration approval
or implanted devices would be an important step toward ensuring
hat we are providing safe care for women with heart failure.
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e appreciate the insightful remarks of Drs. Dhruva and Redberg
n our paper (1). We agree that to improve health care for women,
